PTGX PROTAGONIST THERAPEUTICS INC
2026Q1 · CUSIP 74366E102 · Sector: Healthcare & Biotech
Fading · Price holds, watch
Holders
310
Δ holders QoQ
-4
Breadth percentile
Top 76%
Whale holders
158
Δ whales
+1
Inst. holding value
$7.6B
New positions
52
Closed positions
56
Price momentum (1Q)
+22.2%
Put / Call
6/8
Breadth history (34 quarters)
Past Lit Events & Aftermath 7 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2025Q4 | Top 14% | +22.2% | — |
| 2025Q1 | Top 6% | +23.4% | +86.0% |
| 2024Q3 | Top 4% | -4.1% | +13.7% |
| 2024Q1 | Top 9% | +36.3% | +33.7% |
| 2023Q2 | Top 6% | -11.2% | +52.3% |
| 2020Q4 | Top 17% | +11.3% | +77.1% |
| 2019Q3 | Top 19% | -9.6% | +50.8% |
Options Sentiment
Put holders
6
QoQ: +1
Call holders
8
QoQ: -5
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-1.81
EPS YoY
-332.1%
Revenue (TTM)
$0.1B
Revenue YoY
-64.4%
Net margin
-154.9%
ROE
-17.5%
Debt ratio
6.0%
FCF (TTM)
-$118M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.